Background:
Some aggressive cancers have missing genes in their tumors, specifically SMARCB1 or SMARCA4. These types of tumors are often harder to treat and may not respond well to standard therapies.
This study is testing two immunotherapy drugs:
Tiragolumab blocks a protein called TIGIT, which activates the immune cells to help fight the cancer more strongly.
Cancer cells often use a protein called PD-L1 to hide from the immune system. Atezolizumab blocks PD-L1, helping the immune system recognize the cancer cells as harmful, and attack them.
The Trial:
This study will investigate whether Tiragolumab and Atezolizumab are safe and effective at shrinking and controlling the tumors.
The study has two treatment groups, mainly based on age. All patients will receive Tiragolumab and atezolizumab, but how and when they get the drugs is slightly different.
- Pediatric Regime (Those under 18 years old): Testing if Tiragolumab is safe for children
- Adult Regime: Testing how well the combination works against cancer.
This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.
Basic Eligibility:
- Must have SMARCB1 or SMARCA4-deficient tumors (Renal medullary carcinoma)
- Relapsed cancer, not responding to treatment, or newly diagnosed with no known therapy that can be used
Additional eligibility criteria will apply. Please speak to your doctor.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentreHospital for Sick Children | Principal InvestigatorNot Given | LocationToronto, ON | Trial StatusSuspended |
Hospital / Cancer CentreCentre Hospitalier Universitaire Sainte-Justine | Principal InvestigatorNot Given | LocationMontreal, QC | Trial StatusSuspended |